Latest News
Novo buying up ‘more of its supply chain’ in Single Use Systems deal
Novo buying up ‘more of its supply chain’ in Single Use Systems deal
Novo Holdings, the investment company behind pharma giant Novo Nordisk, will acquire a controlling stake in bioprocess fluid management firm Single Use Support.
Deal-Making
Johnson & Johnson (J&J) will acquire bispecific antibody developer Proteologix for $850 million in cash and additional milestone payments.
Novo Holdings, the investment company behind pharma giant Novo Nordisk, will acquire a controlling stake in bioprocess fluid management firm Single Use Support.
Facilities & Capacity
Bolt Biotherapeutics outlined plans to halve its workforce as part of a “strategic refocusing” that will see the firm stop development of antibody conjugate candidate trastuzumab imbotolimod.
Sanofi will double production capacity at a monoclonal antibody (mAb) facility near Paris as part of a major investment in its home country France.
Global Markets
.jpg?width=700&auto=webp&quality=80&disable=upscale)
Experts at Abu Dhabi Global Healthcare Week (ADGHW), United Arab Emirates (UAE) discussed the importance of having multiple stakeholder conversations to facilitate the transition from healthcare to health globally.
A revised version of the US BIOSECURE Act will give US biopharma firms until 2032 to sever ties with Chinese suppliers. For WuXi Biologics, this could lead to share buybacks, privatization, or an all-out sale says one analyst.
Regulations
A revised version of the US BIOSECURE Act will give US biopharma firms until 2032 to sever ties with Chinese suppliers. For WuXi Biologics, this could lead to share buybacks, privatization, or an all-out sale says one analyst.
The US FDA has approved Beqvez (fidanacogene elaparvovec), Pfizer’s adeno-associated virus (AAV) based gene therapy for the treatment of hemophilia B.
Therapeutic Class
.jpg?width=700&auto=webp&quality=80&disable=upscale)
CDMO Lonza cites the improving funding landscape, and its own CAPEX is it anticipates growth in 2024.
Sanofi has signed a licensing deal worth up to $1.2 billion with Novavax to commercialize the latter’s adjuvanted COVID-19 vaccine and use the technology to create its own flu shot.
Upstream & Downstream Processing
Novo Holdings, the investment company behind pharma giant Novo Nordisk, will acquire a controlling stake in bioprocess fluid management firm Single Use Support.
Repligen says it is looking at new modalities and its filtration franchise to drive momentum following a mixed first quarter 2024.